The Possible Clinical Beneficial Effects of Atorvastatin in Iraqi Patients with Systolic Heart Failure

Masar S. Baker

Authors

Masar S. Baker

Keywords:

atorvastatin, heart failure, high sensitivity-C reactive protein, tumor necrosis factor-#x3B1;, adiponectin, total antioxidant status, left ventricular ej

Abstract

This study was designed to evaluate the therapeutic effectiveness of atorvastatin in Iraqi patients with systolic heart failure. Sixty heart failure patients were participated in this study and their ages ranged from (35-72) years. The patients were divided into three groups: patients with heart failure and normal lipid profile not receiving atorvastatin (group one), patients with heart failure and normal lipid profile receiving atorvastatin (group two), patients with heart failure and dyslipidemia receiving atorvastatin. Twenty healthy subjects were selected to be a normal group for the purpose of comparison. Several parameters of inflammation and oxidative stress (hs-CRP, TNF-α, total antioxidant status and adiponectin) as well as left ventricular ejection fraction were measured. The study duration was three months and the parameters were measured at baseline, one-half month and three months. The results showed that the serum level of hs-CRP, TNF-α and total antioxidant status were not significantly changed in group one patients, while they were significantly changed in the other two groups.

Downloads

How to Cite

The Possible Clinical Beneficial Effects of Atorvastatin in Iraqi Patients with Systolic Heart Failure. (2012). Global Journal of Medical Research, 12(10), 23-36. https://medicalresearchjournal.org/index.php/GJMR/article/view/100082

Download Citation

References

S Michael, M Figueroa, Jay Peters, M Faarc (2006) Congestive Heart Failure: Diagnosis, Pathophysiology, Therapy, and Implications for Respiratory Care. 51(4).

M Yamani, B Massie (1993) Congestive heart failure: insights from epidemiology, implications for treatment. 68, 1214-1218.

Jiang He, Md, ; Phd, G Lorraine, Lydia Ogden, Bazzano, Phd; Suma, Mph Vupputuri, Catherine Loria, Phd, K Ms; Paul, Whelton, Msc Md (2001) Risk Factors for Congestive Heart Failurein US Men and Women. 161.

Kenneth Dickstein, ; Norway, ), Alain Cohen-Solal (france, ) (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides: reply. 30(3), 383-383.

Carol Porth (2007) Essentials of pathphysiology.

Lars Pal Aukrust1, Thor Gullestad, Jan Ueland, Arne Dama, Yndestad (2005) Inflammatory and anti-inflammatory cytokines in chronic heartfailure: Potential therapeutic implications. 37, 74-85.

Carlene Hamilton, William Miller, Al-Benna Sammy, M Julia, Russell Brosnan, Martin Drummond, Anna Mcbride, Dominiczak (2004) Strategies to reduce oxidative stress incardiovascular disease. 106, 219-234.

Kanu Chatterjee, Barry Massie (2007) Systolic and Diastolic Heart Failure: Differences and Similarities. 13(7), 569-576.

Kim Sutherland (2010) Bridging the quality gap:Heart failure. 978, 1-906461.

F D R Hobbs, J Doust, J Mant, M Cowie (2012) Diagnosis of heart failure in primary care. 96(21), 1773-1777.

Cardio_Ascular Sticares, P Research Foundation, Box Unknown Title. 882, 416-485.

Sweden Go¨teborg (2002) Comprehensive guidelines for the diagnosis and treatment of 15. Maciej Banach1, Jarosław Drożdż, Piotr Okonski1 Insulin Resistance and Related Complications. 53, 123-129.

Joshua Hare (2001) Oxidative Stress and Reactive Protein Assay as a Risk Marker. 116(Suppl 1), 108-S115.

O Paul, Collinson (2009) Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Apoptosis in Heart Failure Progression. 89, 198-200.

Federico Cacciapuoti (2010) Are Clinical Heart Failure and Ejection Fraction Always Connected?. 3, 1-8.

Khayatnouri Mirhadi, ; Tobias Pischon, Cynthia Girman, Nader Rifai, Gokhan Hotamisligil, Eric Rimm (2012) Association between dietary factors and plasma adiponectin concentrations in men. 81(6), 636-641.

Charalambos Vlachopoulos, Konstantinos Aznaouridis, Anna Dagre, Carmen Vasiliadou, Constantina Masoura, Elli Stefanadi, John Skoumas, Christos Pitsavos, Christodoulos Stefanadis (2007) Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. 28(17), 2102-2109.

K Trinath, Mishra (2008) Role of Statins in Heart Failure. 9(2), 108-114.

M Thozhukatsathyapalan, Mrcp Stephen L, Atkin, Frcp, Eric Phd, Kilpatrick, Frcpath Md, Frcp(e)d (2010) Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes. 33(9).

Ruth Weinstock, Ronald Goldberg, John Guyton, Theodore Mazzone, Adam Polis, Joanne Tomassini, Jianxin Lin, Arvind Shah, Andrew Tershakovec (2008) Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. 2(1), 25-35.

M Ishwarlaljialal, Phd, Path, Phd Sridevidevaraj (2001) The Value of the High-Sensitivity C-Reactive Protein Assay as a Risk Marker. 116(Suppl 1), 108-S115.

Sarana Boonbaichaiyapruck, M, Sayan Cheepudomwit, M, Pradit Panjavenin, M, Taworn Suthichaiyakul, M, Worachart Moleelerkpoom, M, Thanawat Benjanuwatra, M, Bancha Sukanandachai, M, Adisai Buakhamsri, M (2008) Effect of Atorvastatin on LDL & hs-CRP in a Selected Thai Population. 91(8), 1189-1195.

Lyle Best, Ying Zhang, Elisa Lee, Jeun-Liang Yeh, Linda Cowan, Vittorio Palmieri, Mary Roman, Richard Devereux, Richard Fabsitz, Russell Tracy, David Robbins, Michael Davidson, Aftab Ahmed, Barbara Howard (2005) C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes. 112(9), 1289-1295.

Eugene Braunwald, M (2008) Biomarkers in Heart Failure. 358(20), 2148-2159.

(2001) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. NCEP-ATP III (CHD Risk Calculator). 21(6), 661-672.

Von Stephan, Haehling (2009) Statins for heart failure: still caught in no man's land?. 116, 37-39.

Stumpf Christian, Petzi Sebastian, Seybold Katrin, Gerald Martin, Arnold Dorette, Raaz Atilla, Yilmaz, Werner Daniel, Christoph Garlichs (2009) Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. 116, 45-52.

Takayoshi Tsutamoto, Masayuki Yamaji, Chiho Kawahara, Keizo Nishiyama, Masanori Fujii, Takashi Yamamoto, Minoru Horie (2009) Effect of simvastatin vs. rosuvastatin onadiponectin and haemoglobin A1c levels inpatients with nonischaemic chronic heart failure. 11, 1195-1201.

Philip Yu-An, Pai-Feng Ding, Tse-Min Hsu, Lu (2009) Statin Therapy on Insulin Resistance and Plasma Level of Adiponectinin Non-Diabetic, Hypercholesterol-emic Patients. 25, 183.

Carlene Hamilton, William Miller, Sammy Al-Benna, M Julia Brosnan, Russell Drummond, Martin Mcbride, Anna Dominiczak (2004) Strategies to reduce oxidative stress in cardiovascular disease. 106(3), 219-234.

Mohammad Nasar, Abdalla Jarrari, Mohammad Naseer, Tarannum Subhani, Beena Shetty, Faiyaz Shakeel (2009) Antioxidant status of atorvastatin in hypercholesterolemic patients. 74(10), 1063-1073.

Hongjiang Li, Francesco Chen, Tatsuya Romeo, Tom Sawamura, Jawahar Saldeen, Mehta (2002) Statins Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1. 302, 34959-991282.

J Steven, Miller (2001) Emerging mechanisms for secondary cardioprotective effects of statins. 52, 5-7.

S-M Ko, Y-J Kim, J-H Park, N-M Choi (2010) Assessment of left ventricular ejection fraction and regional wall motion with 64-slice multidetector CT: a comparison with two-dimensional transthoracic echocardiography. 83(985), 28-34.